Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications

Area of Science:

• Urology
• Health Economics
• Pharmacoeconomics

Background:

• Benign prostatic hyperplasia (BPH) is a prevalent chronic condition in aging men, necessitating long-term medical management.
• Lifelong medication expenses for BPH can significantly impact patient adherence and overall healthcare costs.
• An aging demographic exacerbates the financial burden of BPH due to polypharmacy.

Purpose of the Study:

• To analyze geographic variations in the out-of-pocket costs of generic benign prostatic hyperplasia (BPH) medications.
• To enhance drug price transparency and improve patient access to affordable BPH treatments.
• To identify factors influencing price disparities in generic BPH drug markets.

Main Methods:

• Pharmacies within a 25-mile radius were categorized (chain, wholesale, independent).
• Out-of-pocket prices for 30-day supplies of common generic BPH medications (tamsulosin, finasteride, oxybutynin) were collected via telephone survey.
• Multivariable linear regression examined associations between demographic/socioeconomic factors and drug pricing.

Main Results:

• A 93% response rate yielded data from 255 pharmacies across 173 census tracts.
• Median out-of-pocket prices for generic BPH drugs showed up to a 5.5-fold variation between pharmacies.
• No significant association was found between demographic/socioeconomic factors and generic BPH drug price variations.

Conclusions:

• Significant geographic variability exists in the out-of-pocket pricing of generic BPH medications within localized areas.
• The study underscores the critical need for quality improvement initiatives focused on price comparison and transparency for patients.
• Empowering patients with price comparison tools is essential for improving access to affordable BPH medications.